Krystal Biotech, Inc.
KRYS
$346.17
-$1.92-0.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 440.48M | 417.30M | 389.13M | 373.16M | 359.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 440.48M | 417.30M | 389.13M | 373.16M | 359.21M |
| Cost of Revenue | 23.62M | 24.34M | 23.05M | 21.41M | 23.83M |
| Gross Profit | 416.87M | 392.96M | 366.08M | 351.76M | 335.38M |
| SG&A Expenses | 159.89M | 155.11M | 146.74M | 136.58M | 127.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.73M | 238.57M | 227.84M | 214.76M | 207.21M |
| Operating Income | 197.75M | 178.73M | 161.30M | 158.40M | 152.00M |
| Income Before Tax | 226.62M | 207.32M | 189.47M | 186.95M | 168.75M |
| Income Tax Expenses | -14.85M | -17.72M | -15.36M | -11.96M | 22.03M |
| Earnings from Continuing Operations | 241.47 | 225.03 | 204.83 | 198.91 | 146.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 241.47M | 225.03M | 204.83M | 198.91M | 146.73M |
| EBIT | 197.75M | 178.73M | 161.30M | 158.40M | 152.00M |
| EBITDA | 199.29M | 180.47M | 162.92M | 159.73M | 153.36M |
| EPS Basic | 8.27 | 7.74 | 7.07 | 6.89 | 5.09 |
| Normalized Basic EPS | 4.84 | 4.46 | 4.09 | 4.05 | 3.93 |
| EPS Diluted | 7.98 | 7.48 | 6.85 | 6.68 | 4.93 |
| Normalized Diluted EPS | 4.67 | 4.30 | 3.96 | 3.92 | 3.80 |
| Average Basic Shares Outstanding | 116.86M | 116.24M | 115.77M | 115.43M | 115.20M |
| Average Diluted Shares Outstanding | 121.25M | 120.34M | 119.70M | 119.34M | 119.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |